VectivBio

VectivBio is a biotechnology company dedicated to developing transformative therapies for severe rare diseases. Headquartered in Basel, Switzerland, with business operations in the New York area, VectivBio focuses on identifying and developing treatments for conditions with well-defined biology that can be targeted with tailored therapies. The company serves patients suffering from severe rare diseases, such as Short Bowel Syndrome with Intestinal Failure (SBS-IF), a rare and debilitating condition. VectivBio operates in the global biopharmaceutical market, leveraging its expertise in bioprocess development and rare disease drug development to create innovative solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the successful launch and lifecycle management of biotech and small molecule products. The company's patient-centric approach ensures that the needs and experiences of patients are at the forefront of its mission to improve lives.

Keywords: biotechnology, rare diseases, patient-centric, transformative therapies, biopharmaceutical, SBS-IF, Basel, New York, drug development, innovative solutions.